Antiphospholipid antibody syndrome and renal disease

Current Opinion in Nephrology and Hypertension

Volumn 10, Issue 2, 2001, Pages 175-181

  Joseph, Rosy E ^a   Radhakrishnan, Jai ^a,b   Appel, Gerald B ^a  

^a New York Presbyterian Hospital Columbia University Medical Center   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA2 GLYCOPROTEIN 1; CARDIOLIPIN ANTIBODY; IMMUNOSUPPRESSIVE AGENT; PHOSPHOLIPID ANTIBODY; WARFARIN;

ANTIBODY BLOOD LEVEL; ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; DISEASE ASSOCIATION; DRUG EFFECT; GRAFT SURVIVAL; HEMODIALYSIS PATIENT; HEPATITIS C; HUMAN; HYPERCOAGULABILITY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MORBIDITY; MORTALITY; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; HUMANS; KIDNEY DISEASES; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 0035101336     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-200103000-00004     Document Type: Article

References (73)

1. Renal disease in antiphospholipid syndrome (APLS)
2. Antiphospholipid antibody syndrome, renal infarction and hypertension
3. The 'primary' antiphospholipid syndrome: Major clinical and serological features
4. Antiphospholipid antibodies: Anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and non-SLE disorders
5. Prevalence, follow-up and clinical significance of the anticardiolipin antibodies in normal subjects
6. The prevalence of anticardiolipin antibodies in a healthy elderly population and its association with antinuclear antibodies
7. High prevalence of anticardiolipin and other autoantibodies in a healthy elderly population
8. Accuracy of anticardiolipin antibodies in identifying a history of thrombosis among patients with systemic lupus erythematosus
9. Significance of anti-phospholipid antibodies in patients with lupus nephritis
10. Anticardiolipin antibody in patients on maintenance hemodialysis and its association with recurrent arteriovenous graft thrombosis
11. A large prospective survey of anticardiolipin antibodies in chronic hemodialysis patients
12. Thrombosis, recurrent fetal loss, and thrombocytopenia: Predictive value of the anticardiolipin antibody test
13. Heterogeneity of anticardiolipin antibodies defined by the anticardiolipin cofactor
14. Anti-beta2-glycoprotein I antibodies: Detection and association with thrombosis
15. Anti-beta2-glycoprotein I antibodies: A marker of the antiphosphplipid syndrome?
16. Antibodies to endothelial cells and to beta2-glycoprotein I in the antiphospholipid syndrome: Prevalence and isotype distribution
17. Antibodies to beta2-glycoprotein I and clinical manifestations in patients with systemic lupus erythematosus
18. Comparison of an enzyme-linked immunosorbent assay for antibodies to beta2-glycoprotein I and a conventional anticardiolipin immunoassay
19. Do antibodies to beta2-glycoprotein I contribute to the better characterization of the antiphospholipid syndrome?
20. Antiphospholipid antibodies are an epiphenomenon in HIV-infected patients
21. High prevalence of anticardiolipin antibodies in hepatitis C virus infection: Lack of effects on thrombocytopenia and thrombotic complications
22. Anticardiolipin antibodies in patients with hepatitis C virus infection: Characterization in relation to antiphospholipid syndrome
23. Increased soluble vascular cell adhesion molecule I concentrations in patients with primary or systemic lupus erythematosus-related antiphospholipid syndrome. Correlations with severity of thrombosis
24. Antiphospholipid syndrome and renal artery stenosis
25. Antiphospholipid antibodies are directed against epitopes of oxidized phospholipid
26. Anticardiolipin antibodies and the risk of myocardial infarction in a prospective cohort of middle aged men
27. The prevalence of antibodies to anionic phospholipids in patients with the primary antiphospholipid syndrome, with systemic lupus erythematosus and their relatives and spouses
28. HLA class II alleles associations with anticardiolipin and anti-beta2GPI antibodies in a large series of European patients with systemic lupus erythematosus
29. Anticardiolipin antibodies and lupus anticoagurant
30. Longitudinal determination of antiphospholipid antibodies in lupus patients without previous manifestations of antiphospholipid syndrome. A prospective study
31. Outcome of patients with anticardiolipin antibodies: A 10 year follow-up of 52 patients
32. Anticardiolipin and antibeta2GPI antibodies in a large series of European patients with systemic lupus erythematosus. Prevalence and clinical associations
33. Morbitidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1000 patients
34. Lupus anticoagulant in systemic lupus erythematosus: A clinical and renal pathological study
35. Renal thrombotic microangiopathy in patients with systemic lupus erythematosus and the antiphospholipid syndrome
36. Anti-cardiolipin antibody and renal disease: A report of three cases
37. Renal vascular complications of systemic lupus erythematosus
38. Renal thrombotic microangiopathy associated with multicentric Castleman's disease. Report of two cases
39. Glomerular thrombosis in systemic lupus erythematosus: Prevalence and significance
40. Association of anticardiolipin antibodies with intraglomerular thrombi and renal dysfunction in lupus nephritis
41. Lupus anticoagulant associated with renal thrombotic microangiopathy and pregnancy related renal failure
42. Renal vascular disease in patients with primary antiphospholipid antibodies
43. Antiphospholipid antibodies and the kidney
44. A reversible bilateral renal artery stenosis in association with the antiphospholipid syndrome
45. Antiphospholipid (aPL) antibodies in end stage renal disease
46. Prevalence and clinical significance of antiphospholipid antibodies in renal transplant recipients
47. Antiphospholipids in hemodialysis patients: Relationship between lupus anticoagulant and thrombosis
48. Anticardiolipiin antibody in patients on maintenance hemodialysis and its association with recurrent AV graft thrombosis
49. Evidence for ongoing oxidative stress in hemodialysis patients
50. Relationship of anticardiolipin antibodies (ACLA) to oxidative stress in hemodialysis (HD)
51. Antiphospholipid antibodies are a risk factor for early renal allograft failure
52. Outcomes of renal transplantation among patients with end-stage renal disease caused by lupus nephritis
53. Antiphospholipid antibody syndrome in renal transplantation: Occurrence of clinical events in 96 consecutive patients with systemic lupus erythematosus
54. Renal thrombotic microangiopathy associated with anticardiolipin antibodies in hepatitis C-positive renal allograft recipients
55. The management of thrombosis in the antiphospholipid-antibody syndrome
56. Management of the Hughes syndrome
57. Antiphospholipid antibody associated thrombosis: A consensus for treatment?
58. The lupus anticoagulant/antiphospholipid syndrome
59. Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulation treatment
60. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis
61. Lupus anticoagulant and thrombosis in systemic lupus erythematosus
62. Management of the antiphospholipid syndrome
63. Failure of the war to the knife against antiphospholipid antibodies by conventional immunosuppressive therapy in systemic lupus erythematosus
64. Fetal survival after prednisone suppression of maternal lupus anticoagulant
65. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients
66. Relation of antiphospholipid antibody and placental bed inflammatory changes to the outcome of pregnancy in successive pregnancies in 2 women with systemic lupus erythematosus
67. Transient disappearance of serum antiphospholipid antibodies can also be due to prednisone therapy
68. The catastrophic antiphospholipid syndrome
69. Catastrophic antiphospholipid syndrome. Clinical and laboratory features of 50 patients
70. Diagnosis and management of antiphospholipid syndrome
71. The antiphospholipid antibodies in SLE: Symptomatic therapy or war to the knife?
72. Answers to the antiphospholipid antibody syndrome?
73. Anticardiolipin antibody levels in lupus nephritis: Effects of immunosuppression